Introduction
Lifarizine (RS-87476) is a diphenylpiperazine analogue that is neuroprotective in a number of animal models of focal and global cerebral ischaemia (Alps et al., 1990; Kucharczyk et al., 1991; Brown et al., 1993; . Furthermore, lifarizine has shown early promise in a small-scale clinical trial designed to assess its safety and tolerance in the treatment of acute ischaemic stroke (Squire et al., 1994) . This neuroprotective action is thought to be mediated via an interaction of the compound with CNS voltage-gated sodium channels. Thus, lifarizine potently inhibits the neurotoxic effects of the sodium channel activator, veratridine, on rat cerebrocortical neurones in culture (May et al., 1995) and exerts a potent voltage-dependent inhibition of neuronal sodium currents, an action that is mediated by a preferential interaction of lifarizine with inactivated sodium channels (McGivern et al., 1995) . This latter action is very similar to that produced by a number of other agents which are believed to exert their therapeutic actions via an inhibition of sodium currents. For example, local anaesthetics inhibit sodium currents by an interaction with the inactivated state of the channel (for review, see Catterall, 1987) .
It has been recognised for some time that there is a good correlation between the abilities of many agents to inhibit sodium currents and their abilities to displace the sodium channel activator, [3H]-batrachotoxin-A 20-cx-benzoate (BTX), from its binding site (Postma & Catterall, 1984) . BTX and other toxins have been used to probe sodium channel structure and func- ' Author for correspondence.
tion. A number of toxin binding sites have been defined for the sodium channel: tetrodotoxin (TTX) and saxitoxin (STX) bind to site 1 to inhibit sodium flux through the channel (Catterall, 1981) ; BTX, veratridine and aconitine bind to site 2 to induce persistent activation of the channel (Catterall, 1981; Hille et al., 1987) ; the a-scorpion toxins and sea anemone toxins interact at site 3 to slow inactivation and potentiate the actions of toxins at site 2 (Lazdunski et al., 1986) ; P-scorpion toxins bind to site 4 to induce a hyperpolarizing shift of the voltagedependence of channel activation (Couraud et al., 1982) ; the brevetoxins and the ciguatoxins bind to site 5, shift the voltagedependence of channel activation and enhance the binding of toxins at sites 2 and 4 (Catterall & Risk, 1981; Poli et al., 1986) ; pyrethroids and DDT act via a sixth unique site to cause persistent activation and also greatly enhance the binding of toxins to site 2 (Lombet et al., 1988) . The local anaesthetic, tetracaine (Reith et al., 1987) , the putative local anaesthetic, PD85,639 (Thomsen et al., 1993) and the anticonvulsant agent, phenytoin (Francis & Burnham, 1992) , have been radiolabelled and used as probes to determine if they bind to novel sites on the voltage-gated sodium channel specific for the different therapeutic agents. Both classes of compounds allosterically interact with toxin site 2, although evidence suggests that local anaesthetic and anticonvulsant drugs do not bind to the same site on the sodium channel, as anticonvulsants (100 JiM) do not compete for [3H]-PD85,639 binding (Thomsen et al., 1993) and local anaesthetics have very low affinity for [3H]-phenytoin binding (Francis & Burnham, 1992) . Recently the location of the anaesthetic receptor site in the pore of the sodium channel has been defined (Ragsdale et Brftish Journal of Pharmacology (1995) 115, [1103] [1104] [1105] [1106] [1107] [1108] [1109] [3KH-1lfarizine binding to sodium channels al., 1994) . In the present study we have characterized the binding of the cerebral anti-ischaemic agent, [3H]-lifarizine, to rat brain sodium channels and have investigated the functional relevance of the binding site in electrophysiological experiments in voltage-clamped neuroblastoma cells.
Methods
[3H]-lifarizine binding to rat cerebrocortical membranes Male Sprague-Dawley rats (180-200 g) were decapitated and the cerebral cortex separated from other brain regions over ice. Membranes were prepared by homogenization in 25 volumes of ice-cold 50 mM Tris HCl (pH 7.4 at 25'C) with a Polytron PT 10 tissue disruptor. The homogenate was centrifuged at 48000 g for 15 min at 40C. The pellet was resuspended in the same buffer and washed 3 times by resuspension and centrifugation. The final pellet was resuspended in Tris HCl buffer at an approximate protein level of 3 mg ml[', snap frozen in liquid N2 and stored at -80'C until required. Binding assays were initiated by the addition of membrane protein (150-200 jg.) to 50 mm Tris HCO (pH 7.4) containing 0.01% bovine serum albumin (BSA), 1 nM [3H]-lifarizine and various concentrations of test drugs (500 jl final assay volume). Nonspecific binding was determined in the presence of 1 jM lifarizine or 3 jM flunarizine. Reactions were incubated for 90 min at 250C and bound ligand was separated from free by vacuum filtration through Whatman GF/B filters presoaked for 30 min in assay buffer containing 0.01% polyethylenimine. The filters were washed with 3 x 5 ml assay buffer and bound ligand was estimated by liquid scintillation spectrometry. Protein content was determined with protein assay kits (Pierce BSA) using BSA as the protein standard. 
Solubilization and reconstitution into phospholipid vesicles
Membranes were prepared from 2 rat cortices (see above) in ice-cold 50 mM Tris HCl buffer (pH 7.4 at 25°C) containing 1 mM EGTA and the protease inhibitors, phenyl methyl sulphonyl fluoride (PMSF; 0.1 mM), iodoacetamide (1 mM), phenanthroline (1 mM) and pepstatin A (1 jiM). Membrane protein (40-50 mg) was suspended in 20 ml 10 mM HEPES (pH 7.4) containing protease inhibitors, 100 mM KCl, phosphatidyl choline (0.25% w/v) and detergent (2.5% Triton X-100, 0.3% sodium cholate or 1% P-octyl glucoside).
The mixture was stirred on ice for 15 min before centrifugation at 120000 g for 75 min at 4°C. Solubilized sodium channels were reconstituted into phosphatidylcholine: phosphatidylethanolamine (65%:35%) vesicles as previously described (Feller et al., 1985) .
Binding Cells were clamped at a holding potential of -100 mV and control sodium currents were evoked by 10 ms depolarizing steps to 0 mV. Following establishment of a stable current, cells were exposed to a single concentration of drug for 10 min. The membrane potential was then clamped to a conditioning potential of 0 mV for 20 s, after which it was returned to -100 mV and a series of test depolarizations to 0 mV were made to probe recovery from voltage-dependent block. The first test depolarization was elicited 2 s after the conditioning depolarization, with subsequent test depolarizations being evoked at a frequency of 0.2 Hz. Recovery from block followed an exponential time course which was fitted to the following function: relative INa = I-A.exp(-t/r), were t is time (s), r is the time constant of the exponential recovery (s) and A= 1-y intercept value (i.e. the extrapolated current amplitude immediately after the 20 s conditioning depolarization normalised to the pre-conditioning control current amplitude). The apparent dissociation constant (apparent Kb) of compounds for inactivated sodium channels was calculated from the following relation:
( 1) where [b] [3PH-lifarizine binding to sodium channels 
Solubilization and reconstitution studies
Rat cerebrocortical membranes were solubilized with Triton X-100, as described by Hartshorne & Catterall (1984) . Phosphatidylcholine was included in the solubilization buffer because the presence of lipid has been found to increase greatly the stability of the a-subunit (Agnew & Raftery, 1979; Hartshorne & Catterall, 1981 izine (1 gM; n = 4); flunarizine (1 gM; n = 4); KB-2796 (3 gM; n = 3); PD85,639 (3 gM; n = 3); phenytoin (50 and 100 jM; n = 4 at each concentration); lignocaine (30, 100 and 300 gM; n = 1 at each concentration). An example of the estimation of apparent Kb for lifarizine is illustrated in Figure 5 (control 0 t1/2 > 500 min) but was greatly accelerated by 1 jiM lifarizine (0 t1/2 = 52 min and K-1 = 0.0234 min'). In this example, the data points are well-described by a monoexponential function which gives an estimate for A of 0.855. The calculated apparent affinity (Kb) for the inactivated state of sodium channel is 0.17JIM. Solubilization of the sodium channel with Triton X-100, under the conditions described by Hartshorne & Catterall (1984) (Isom et al., 1994) was some 10 fold higher than under normal conditions. Indeed, the affinity of
[3H]-lifarizine in depolarized synaptosomes was similar to its affinity in cerebrocortical membranes. The most likely explanation for these findings is that lifarizine binds selectively to inactivated sodium channels, since these will predominate both in the membrane preparation and in the depolarized synaptosomal preparation. The lower affinity of [3H]-lifarizine in nondepolarized synaptosomes may be due to a proportion, albeit unknown, of the sodium channels in this preparation being in the resting state, for which lifarizine has very low affinity (McGivern et al., 1995) .
Electrophysiological studies have demonstrated that lifarizine has negligible interaction with the open state of the sodium channel (McGivern et al., 1995) . In contrast, [3H]-BTX interacts preferentially with open sodium channels (Catterall, 1980 
